2013 | A cross-sectional study of factors related to gastrointestinal drug use in Korean adolescents | 곽혜선; 이병구; 이정연; 배승진 | Article |
2020 | A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients' Experience | 배승진; 이동환 | Article |
2014 | Analysis of statistical methods currently used in toxicology journals | 배승진; 임경민 | Article |
2015 | Appraisal of within- and between-laboratory reproducibility of non-radioisotopic local lymph node assay using flow cytometry, LLNA: BrdU-FCM: Comparison of OECD TG429 performance standard and statistical evaluation | 배승진; 임경민 | Article |
2020 | Are Recently Evaluated Drugs More Likely to Receive Positive Reimbursement Recommendations in South Korea? 11-year Experience of the South Korean Positive List System | 배승진; 임경민; 이동환 | Article |
2019 | Availability of Cancer Drugs in Thirteen Developed Countries | 조혜원 | Master's Thesis |
1996 | Baculovirus 곤충세포 발현체계를 이용한 사람의 무스카린성 아세틸콜린 수용체 subtype Hm1과 Hm2의 발현 | 배승진 | Master's Thesis |
2019 | Compliance with Antidepressant Medication in Korea | 원미미 | Master's Thesis |
2021 | Computed tomographic measurements of the psoas muscle as a predictor of mortality in hip fracture patients: Muscle attenuation helps predict mortality in hip fracture patients | 배승진; 이선화 | Article |
2022 | Corporate social responsibility of pharmaceutical industry in Korea | 배승진; 임경민; 안정훈; 배그린 | Article |
2021 | Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future | 배승진 | Article |
2019 | Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-US Free Trade Agreement in Korea | 배승진; 손경복 | Article |
2019 | Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea | 배승진 | Article |
2016 | Eight-year experience of using HTA in drug reimbursement: South Korea | 배승진 | Article |
2017 | Evaluation of radioisotopic and non-radioisotopic versions of local lymph node assays for subcategorization of skin sensitizers compliant to UN GHS rev 4 | 배승진; 임경민 | Article |
2019 | Evaluation of skin sensitization potential of chemicals by local lymph node assay using 5-bromo-2-deoxyuridine with flow cytometry | 배승진 | Article |
2016 | Exploration and comparison of in vitro eye irritation tests with the ISO standard in vivo rabbit test for the evaluation of the ocular irritancy of contact lenses | 배승진; 임경민 | Article |
2016 | FACTORS ASSOCIATED WITH POTENTIALLY INAPPROPRIATE MEDICATION USE IN ELDERLY KOREANS IN AN OUTPATIENT SETTING: A POPULATION-BASED STUDY | 배승진 | Letter |
2016 | Factors associated with the Career Preference of 6-Year Doctor of Pharmacy (Pharm.D) Students in Korea: a National Survey | 배승진 | Article |
2019 | Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study | 배승진; 이동환; 최남경 | Article |
2021 | How can we improve patients’ access to new drugs under uncertainties? : South Korea’s experience with risk sharing arrangements | 배승진; 손경복 | Article |
2022 | How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea | 배승진 | Article |
2022 | Impact and challenges of enactment for advanced regenerative medicine in South Korea | 배승진 | Review |
2013 | Impact of high fat diet-induced obesity on the plasma levels of monoamine neurotransmitters in C57BL/6 Mice | 배승진; 임경민 | Article |
2012 | Incidence and 30-day mortality of peptic ulcer bleeding in Korea | 심기남; 배승진 | Article |
2012 | Incidence and short-term mortality from perforated peptic ulcer in Korea: A population-based study | 심기남; 배승진 | Article |
2020 | Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea | 배승진; 이동환; 손경복 | Article |
2014 | KeraSkin™-VM: A novel reconstructed human epidermis model for skin irritation tests | 배승진; 임경민 | Article |
2017 | KeraSkin™-VM을 이용한 피부자극성 동물대체시험법 검증연구 | 한아람 | Master's Thesis |
2022 | Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version | 배승진 | Article |